Processa Pharmaceuticals, Inc. — Director's Dealing 2020

Oct 2, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Processa Pharmaceuticals, Inc. (PCSA)
CIK: 0001533743
Period of Report: 2020-10-02

Reporting Person: Young David (Director, Chief Executive Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	335190	Direct
Common Stock	548783	Indirect
Common Stock	689004	Indirect
Common Stock	55258	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Options (Right to Buy)	$16.80	2024-06-20	Common Stock (7859)		Direct
Stock Options (Right to Buy)	$16.80	2024-06-20	Common Stock (8664)		Direct
Warrants (Right to Buy)	$19.068	2021-06-29	Common Stock (3147)		Direct
Warrants (Right to Buy)	$19.068	2021-06-29	Common Stock (20309)		Indirect
Warrants (Right to Buy)	$19.068	2021-06-29	Common Stock (15734)		Indirect
Warrants (Right to Buy)	$17.164	2021-05-25	Common Stock (14731)		Indirect

Footnotes

F1: Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.

F2: Stock options vest upon meeting certain performance criteria.

F3: Need warrant info here